A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Trial Profile

A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 30 Apr 2018.
    • 06 Jun 2017 Results (n=24) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 12 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top